| Solis Minerals Ltd (SLM) ORDINARY FULLY PAID |
Materials |
$20 |
Mineralisation intersected at Chancho al Palo, Peru
|
23 Jun 2025 8:43AM |
$0.096 |
$0.078 |
fallen by
18.75%
|
|
SLM - Price-sensitive ASX Announcement
Full Release
Key Points
- Solis Minerals Ltd announced the intersection of broad zones of copper and gold mineralisation at Chancho al Palo, Peru.
- Initial drilling at Ilo Este Project has yielded significant mineralisation results.
- The results confirm the presence of a large mineralised system with potential for further discovery.
- Drill holes intersected substantial widths of mineralisation carrying copper and gold values.
- The mineralisation is hosted in intrusive rocks, interpreted as part of a porphyry system.
- Geological interpretation supports ongoing and expanded exploration at the site.
- Future drilling and exploration are planned to define the extent and grade of the mineralised zones.
- The announcement underscores the company's confidence in the potential of the Ilo Este Project.
- Solis Minerals is committed to advancing exploration based on these encouraging results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$145 |
Cleansing Notice - Share and Option Issue
|
23 Jun 2025 8:43AM |
$0.041 |
$0.069 |
risen by
68.29%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$9,829 |
Form 8-K - CLO transition
|
23 Jun 2025 8:43AM |
$128.700 |
$121.070 |
fallen by
5.93%
|
|
| Optiscan Imaging Limited (OIL) ORDINARY FULLY PAID |
Health Care |
$115 |
Optiscan Signs Agreement with Long Grove Pharmaceuticals
|
23 Jun 2025 8:41AM |
$0.110 |
$0.110 |
fallen by
0%
|
|
OIL - Price-sensitive ASX Announcement
Full Release
Key Points
- Optiscan Imaging Limited (OIL) has signed an agreement with Long Grove Pharmaceuticals, LLC.
- The agreement is focused on the commercialization and distribution of Optiscan’s digital pathology solutions in the United States.
- The partnership aims to accelerate the adoption of Optiscan’s real-time digital imaging technology in clinical and diagnostic markets.
- Long Grove Pharmaceuticals will utilize its established U.S. distribution network to market Optiscan’s products.
- The collaboration is expected to expand Optiscan’s market presence and drive revenue growth.
- This strategic move aligns with Optiscan’s goal to expand into North American healthcare and research sectors.
- The agreement includes plans to deliver Optiscan’s advanced imaging solutions to hospitals, clinics, and research institutions.
- The partnership is anticipated to enhance Optiscan’s brand recognition within the U.S. healthcare market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$145 |
Application for quotation of securities - RML
|
23 Jun 2025 8:41AM |
$0.041 |
$0.069 |
risen by
68.29%
|
|
| Engenco Limited (EGN) ORDINARY FULLY PAID |
Industrials |
- |
Change in substantial holding
|
23 Jun 2025 8:41AM |
$0.305 |
$0.305 |
fallen by
0%
|
|
| Janus Henderson Global Sustainable (Managed Fund) (FUTR) |
Financials |
$2 |
FUTR - June 2025 Distribution Timetable
|
23 Jun 2025 8:40AM |
$38.680 |
$37.900 |
fallen by
2.02%
|
|
| Intelligent Monitoring Group Limited (IMB) ORDINARY FULLY PAID |
Industrials |
$226 |
IMB - Release of Securities from Voluntary Escrow
|
23 Jun 2025 8:40AM |
$0.530 |
$0.550 |
risen by
3.77%
|
|
| Metcash Limited (MTS) ORDINARY FULLY PAID |
Consumer Staple |
$3,101 |
FY25 Full Year Results Presentation
|
23 Jun 2025 8:39AM |
$3.700 |
$2.820 |
fallen by
23.78%
|
|
MTS - Price-sensitive ASX Announcement
Full Release
Key Points
- Metcash delivered strong sales and profit growth in FY25 despite a volatile economic environment.
- The Hardware segment continued to outperform, with record sales and improved earnings.
- Food and Liquor divisions showed resilience with ongoing improvements in market share and profitability.
- Significant investments were made in supply chain infrastructure, digital initiatives, and strategic partnerships.
- Metcash maintains a disciplined approach to cost control and capital management.
- The company continues to support and grow the independent retail network across its core sectors.
- Focus areas include operational excellence, enhancing customer value, and expanding market opportunities.
- Macroeconomic challenges such as inflation and changing consumer behavior were actively managed.
- Metcash remains committed to delivering sustainable returns for shareholders.
- Future outlook includes continued investment in growth initiatives and further strengthening of core business segments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$145 |
Application for quotation of securities - RML
|
23 Jun 2025 8:38AM |
$0.041 |
$0.069 |
risen by
68.29%
|
|
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$28,887 |
Update - Notification of buy-back - ALL
|
23 Jun 2025 8:38AM |
$67.200 |
$47.900 |
fallen by
28.72%
|
|
| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,593 |
Update - Notification of buy-back - KAR
|
23 Jun 2025 8:36AM |
$2.070 |
$2.240 |
risen by
8.21%
|
|
| Metcash Limited (MTS) ORDINARY FULLY PAID |
Consumer Staple |
$3,101 |
FY25 Results Announcement
|
23 Jun 2025 8:36AM |
$3.700 |
$2.820 |
fallen by
23.78%
|
|
MTS - Price-sensitive ASX Announcement
Full Release
Key Points
- Metcash delivered strong sales and earnings growth for FY25.
- Key segments—Food, Liquor, and Hardware—contributed positively to overall performance.
- Improved operational efficiencies and supply chain investments supported financial results.
- The company expanded its retail network and accelerated digital transformation.
- Metcash gained market share in competitive retail environments.
- Disciplined cost and capital management were maintained throughout the period.
- Focus on sustainability initiatives and responsible business practices was underscored.
- The Board remains confident in the company’s growth strategy and outlook for FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$33 |
Update - Notification of buy-back - CDO
|
23 Jun 2025 8:36AM |
$1.690 |
$2.140 |
risen by
26.63%
|
|
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
- |
Update - Notification of buy-back - D2O
|
23 Jun 2025 8:36AM |
$1.520 |
$1.530 |
risen by
0.66%
|
|
| Tasman Resources Limited (TAS) ORDINARY FULLY PAID |
Materials |
$23 |
EDE: EdenCrete Products - Colorado Market Update
|
23 Jun 2025 8:35AM |
$0.016 |
$0.050 |
risen by
212.50%
|
|
TAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Tasman Resources Limited released a market update for EdenCrete products in Colorado.
- EdenCrete continues to be specified and approved for use in Colorado Department of Transportation (CDOT) projects.
- CDOT has expanded the use of EdenCrete products in various concrete types, including flatwork and bridge decks.
- Testing and trials have demonstrated EdenCrete’s benefits in improving concrete strength and reducing shrinkage and cracking.
- EdenCrete is now being considered and used in additional states and by other transportation authorities.
- New distribution agreements are in place to support market expansion outside Colorado.
- EdenCrete is gaining traction in infrastructure applications such as highways, bridges, and airport projects.
- The company is working closely with contractors and transportation departments to further integrate EdenCrete into specifications.
- Ongoing regulatory and technical approvals are supporting broader market acceptance.
- The announcement emphasizes the growing strategic importance of EdenCrete for infrastructure markets in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Eden Innovations Ltd (EDE) ORDINARY FULLY PAID |
Energy |
$110 |
EdenCrete Products - Colorado Market Update
|
23 Jun 2025 8:35AM |
$0.002 |
$0.190 |
risen by
9,400%
|
|
EDE - Price-sensitive ASX Announcement
Full Release
Key Points
- EdenCrete products are gaining traction in the Colorado infrastructure market.
- Eden Innovations Ltd has focused on sales strategies targeting state and municipal projects.
- The company has secured multiple regulatory approvals for EdenCrete use in concrete applications.
- Collaboration with the Colorado Department of Transportation (CDOT) has facilitated product adoption.
- EdenCrete is being used in road and bridge projects due to its proven durability and performance.
- Ongoing product demonstrations and testing are conducted with contractors and state agencies.
- The report includes feedback from project stakeholders, indicating positive reception and performance.
- Future prospects point to expanded use in Colorado and opportunities for national market growth.
- Eden Innovations continues to monitor and support project implementation to ensure product success.
- The report covers activities and market results up to the first half of 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| D3 Energy Limited (D3E) ORDINARY FULLY PAID |
Energy |
$47 |
Increased flow rates at RBD03 following well clean out
|
23 Jun 2025 8:35AM |
$0.115 |
$0.440 |
risen by
282.61%
|
|
D3E - Price-sensitive ASX Announcement
Full Release
Key Points
- D3 Energy Limited conducted a well clean out at the RBD03 well.
- The intervention was successful and resulted in increased gas flow rates.
- The clean out operation removed blockages and improved reservoir access.
- Post-operation flow rates at RBD03 are higher than previous levels.
- The announcement demonstrates D3E's focus on operational optimization.
- Technical team expertise showcased in successful intervention.
- The company anticipates further production improvements moving forward.
- The update aligns with D3E's ongoing strategy for asset optimization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metcash Limited (MTS) ORDINARY FULLY PAID |
Consumer Staple |
$3,101 |
Dividend/Distribution - MTS
|
23 Jun 2025 8:35AM |
$3.700 |
$2.820 |
fallen by
23.78%
|
|
| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$1,059 |
Contract for Workforce Transportation Services LALNG Project
|
23 Jun 2025 8:35AM |
$3.710 |
$3.900 |
risen by
5.12%
|
|
KLS - Price-sensitive ASX Announcement
Full Release
Key Points
- Kelsian Group Limited awarded major workforce transportation contract for the LALNG Project.
- Contract value is approximately AUD $400 million over five years, with an option for a two-year extension.
- Kelsian will provide transport logistics, bus operations, and scheduling for worker commutes in the Kitimat region.
- The contract was awarded by JGC Fluor BC LNG JV, the main contractor for the LNG Canada Project.
- This award strengthens Kelsian’s presence in the Canadian resources and infrastructure market.
- The agreement aligns with Kelsian’s growth strategy focused on international markets and diversification.
- The project involves safe and efficient transport of a large workforce to a significant LNG development site.
- Kelsian’s experience in complex workforce transportation was a key factor in securing the contract.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metcash Limited (MTS) ORDINARY FULLY PAID |
Consumer Staple |
$3,101 |
Appendix 4E and FY25 Full Year Financial Report
|
23 Jun 2025 8:34AM |
$3.700 |
$2.820 |
fallen by
23.78%
|
|
MTS - Price-sensitive ASX Announcement
Full Release
Key Points
- Metcash Limited delivered strong revenue and earnings growth in FY25.
- Resilient performance across Food, Liquor, and Hardware business segments.
- Ongoing investment in supply chain, digital transformation, and retail store upgrades.
- Support for independent retailers remains a central strategy.
- Disciplined approach to capital allocation and cost management to counter inflationary pressures.
- Final dividend declared, reflecting business confidence.
- Enhanced governance, risk management, and sustainability practices implemented.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stockland (SGP) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$10,189 |
Dividend/Distribution - SGP
|
23 Jun 2025 8:34AM |
$5.600 |
$4.190 |
fallen by
25.18%
|
|
| Immutep Limited (IMM) ORDINARY FULLY PAID |
Health Care |
$103 |
Update on Phase I Study of IMP761 for Autoimmune Diseases
|
23 Jun 2025 8:33AM |
$0.235 |
$0.070 |
fallen by
70.21%
|
|
IMM - Price-sensitive ASX Announcement
Full Release
Key Points
- Immutep Limited provided an update on the Phase I clinical study of IMP761.
- IMP761 is an LAG-3 agonist antibody intended for autoimmune disease treatment.
- The Phase I study is double-blind, placebo-controlled, and single ascending dose, conducted in healthy volunteers in Australia.
- IMP761 was well tolerated at all dose levels with no serious adverse events or dose-limiting toxicities.
- The safety and pharmacokinetics of IMP761 support its further development.
- IMP761’s mechanism targets the root cause of autoimmunity by down-regulating self-reactive T cells.
- Immutep plans to advance IMP761 to further clinical development stages.
- The company will provide additional updates as more clinical data emerges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$581 |
Weekly NTA 20.06.2025
|
23 Jun 2025 8:33AM |
$3.320 |
$2.610 |
fallen by
21.39%
|
|
| Strata Investment Holdings Plc (SRT) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$27 |
Final Director's Interest Notice
|
23 Jun 2025 8:33AM |
$0.160 |
$0.160 |
fallen by
0%
|
|
Call 1300 880 160
Start a chat
Schedule a call
